Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review

Clinical Therapeutics

Volumn 31, Issue SUPPL. 1, 2009, Pages 1426-1453

  Tuccori, Marco ^a,b   Testi, Arianna ^b,c   Antonioli, Luca ^a   Fornai, Matteo ^a   Montagnani, Sabrina ^a,b   Ghisu, Narcisa ^a   Colucci, Rocchina ^a   Corona, Tiberio ^b,c   Blandizzi, Corrado ^a,b   Tacca, Mario Del ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Tuscan Regional Centre of Pharmacovigilance   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

antidepressants; infant; malformations; pregnancy; SSRIs

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; PAROXETINE; REBOXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

BIRTH DEFECT; BRAIN HEMORRHAGE; BRAIN MALFORMATION; CARDIOVASCULAR MALFORMATION; COGNITION; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DEPRESSION; DRUG CLASSIFICATION; DRUG SAFETY; FETOTOXICITY; FETUS RISK; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; INCIDENCE; LOW BIRTH WEIGHT; MATERNAL SMOKING; MONOTHERAPY; MOTHER FETUS RELATIONSHIP; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN DISEASE; OMPHALOCELE; PERSISTENT PULMONARY HYPERTENSION; POSTPARTUM HEMORRHAGE; PREGNANCY; PRENATAL DRUG EXPOSURE; QT PROLONGATION; REVIEW; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SPONTANEOUS ABORTION; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; DEPRESSION; FEMALE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS; TERATOGENS;

EID: 68749119615     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.07.009     Document Type: Review

References (125)

1. Evans J., Heron J., Francomb H., et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 323 (2001) 257-260
2. Josefsson A., Berg G., Nordin C., and Sydsjö G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand. 80 (2001) 251-255
3. Chung T.K., Lau T.K., Yip A.S., et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med. 63 (2001) 830-834
4. Bonari L., Pinto N., Ahn E., et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 49 (2004) 726-735
5. Committee on Drugs, American Academy of Pediatrics. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 105 (2000) 880-887
6. Ververs T., Kaasenbrood H., Visser G., et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 62 (2006) 863-870
7. Bakker M.K., Kölling P., van den Berg P.B., et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 65 (2008) 600-606
8. Ramos E., Oraichi D., Rey E., et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 114 (2007) 1055-1064
9. Nordeng H., and Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: Effects on the infant. Drug Saf. 28 (2005) 565-581
10. Källén B.A., and Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 79 (2007) 301-308
11. Addis A., Sharabi S., and Bonati M. Risk classification systems for drug use during pregnancy: Are they a reliable source of information?. Drug Saf. 23 (2000) 245-253
12. Kulin N.A., Pastuszak A., Sage S.R., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 279 (1998) 609-610
13. Shuey D.L., Sadler T.W., and Launder J.M. Serotonin as a regulator of cranio-facial morphogenesis: Site specific malformations following exposure to serotonin uptake inhibitors. Teratology. 46 (1992) 367-378
14. Moiseiwitsch J.R., and Lauder J.M. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci U S A. 92 (1995) 7182-7186
15. Gershon M.D., Liu K.P., Karpiak S.E., and Tamir H. Storage of serotonin in vivo as a complex with serotonin-binding protein in central and peripheral serotonergic neurons. J Neurosci. 3 (1983) 1901-1911
16. Shuey D.L., Sadler T.W., Tamir H., and Lauder J.M. Serotonin and morphogenesis. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol (Berl). 187 (1993) 75-85
17. Nulman I., Rovet J., Stewart D.E., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 336 (1997) 258-262
18. McElhatton P.R., Garbis H.M., Eléfant E., et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 10 (1996) 285-294
19. Ericson A., Källen B., and Wiholm B. Delivery outcome after the use of anti-depressant in early pregnancy. Eur J Clin Pharmacol. 55 (1999) 503-508
20. Chambers C.D., Johnson K.A., Dick L.M., et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 335 (1996) 1010-1015
21. Pastuszak A., Schick-Boschetto B., Zuber C., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269 (1993) 2246-2248
22. Goldstein D.J., Corbin L.A., and Sundell K.L. Effects of first-trimester fluox-etine exposure on the newborn. Obstet Gynecol. 89 (1997) 713-718
23. Sivojelezova A., Shuhaiber S., Sarkis-sian L., et al. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 193 (2005) 2004-2009
24. Lennestål R., and Källen B. Delivery outcome in relation to maternal use of some recently introduced antide-pressants. J Clin Psychopharmacol 27 (2007) 607-613
25. Maschi S., Clavenna A., Campi R., et al. Neonatal outcome following pregnancy exposure to antidepres-sants: A prospective controlled cohort study. BJOG 115 (2008) 283-289
26. Ramos E., St-André M., Rey E., et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry. 192 (2008) 344-350
27. Wichman C.L., Moore K.M., Lang T.R., et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 84 (2009) 23-27
28. Einarson A., Choi J., Einarson T.R., and Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Can J Psychiatry. 54 (2009) 242-246
29. Cole J.A., Ephross S.A., Cosmatos I.S., and Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 16 (2007) 1075-1085
30. Källén B.A., and Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 79 (2007) 301-308
31. Bérard A., Ramos E., Rey E., et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 80 (2007) 18-27
32. Louik C., Lin A.E., Werler M.M., et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 336 (2007) 2675-2683
33. Alwan S., Reefhuis J., Rasmussen S.A., et al., the National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 356 (2007) 2684-2692
34. Davis R.L., Rubanowice D., McPhillips H., et al., the HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 16 (2007) 1086-1094
35. Oberlander T.F., Warburton W., Misri S., et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 83 (2008) 68-76
36. Diav-Citrin O., Shechtman S., Weinbaum D., et al. Paroxetine and fluox-etine in pregnancy: A prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 66 (2008) 695-705
37. Einarson A., Fatoye B., Sarkar M., et al. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry. 158 (2001) 1728-1730
38. Djulus J., Koren G., Einarson T.R., et al. Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry. 67 (2006) 1280-1284
39. Simon G.E., Cunningham M.L., and Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 159 (2002) 2055-2061
40. Malm H., Klaukka T., and Neuvonen P.J. Risks associated with selective serotonin inhibitors in pregnancy. Obstet Gynecol. 106 (2005) 1289-1296
41. Einarson A., Pistelli A., DeSantis M., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy [published corrections appear in Am J Psychiatry. 2008;165:777, 1208]. Am J Psychiatry. 165 (2008) 749-752
42. Wogelius P., Norgaard M., Gislum M., et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 17 (2006) 701-704
43. GlaxoSmithKline. Bupropion and paroxetine. Study no. EPIP083. Epidemiology study: Preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation. http://www.gsk-clinicalstudyregister.com/files/pdf/2887.pdf Accessed December 31, 2008
44. Paxil and the risk of birth defects. FDA Consum. 40 (2006) 4
45. Williams M., and Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 173 (2005) 1320-1321
46. Yavarone M.S., Shuey D.L., Tamir H., et al. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology. 47 (1993) 573-584
47. Noorlander C.W., Ververs F.F., Nikkels P.G., et al. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS ONE. 3 (2008) e2782
48. Cymbalta (duloxetine hydrochloride) [package insert]. http://pi.lilly.com/us/cymbalta-pi.pdf Accessed April 19, 2009
49. Addis A., and Koren G. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies. Psychol Med. 30 (2000) 89-94
50. Einarson T.R., and Einarson A. Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiol Drugsaf. 14 (2005) 823-827
51. Rahimi R., Nikfar S., and Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-analysis of clinical trials. Reprod Toxicol. 22 (2006) 571-575
52. Bar-Oz B., Einarson T., Einarson A., et al. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther. 29 (2007) 918-926
53. O'Brien L., Einarson T.R., Sarkar M., et al. Does paroxetine cause cardiac malformations?. J Obstet Gynaecol Can. 30 (2008) 696-701
54. Czeizel A.E. Specified critical period of different congenital abnormalities: A new approach for human teratological studies. Congenit Anom (Kyoto) 48 (2008) 103-109
55. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol. 108 (2006) 1601-1603
56. FDA Public Health Advisory. Paroxe-tine. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051731.htm Accessed July 3, 2009
57. Medicines and Healthcare Products Regulatory Agency. MHRA update on the risks of birth defects in babies born to mothers taking paroxetine-Q&A. http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2022700.pdf Accessed July 3, 2009
58. Marden P.M., Smith D.W., and McDonald M.J. Congenital anomalies in the newborn infant, including minor variations. A study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr. 64 (1964) 357-371
59. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 142 (2003) 402-408
60. Bassiouni B.A., and Rafei A.A. 5-Hydroxy-tryptamine (serotonin), copper and ceruloplasmin plasma concentrations in spontaneous abortion. Eur J Obstet Gynecol Reprod Biol. 9 (1979) 81-88
61. Hemels M.E., Einarson A., Koren G., et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis. Ann Pharmacother. 39 (2005) 803-809
62. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 293 (2005) 2372-2383
63. Nordeng H., Lindemann R., Permi-nov K.V., and Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 90 (2001) 288-291
64. Nijhuis I.J., Kok-Van Rooji G.W., and Boss-chaart A.N. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child Fetal Neonatal Ed. 84 (2001) F77
65. Stiskal J.A., Kulin N., Koren G., et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 84 (2001) F134-F135
66. Herbst F., and Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy [in German]?. Z Geburtshilfe Neonatol. 207 (2003) 232-234
67. Agut-Quijano T., Martinez-Nadal S., Elizari-Saco M.J., et al. Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: Case report and literature review [in Spanish]. Rev Neurol. 42 (2006) 660-662
68. Dahl M.L., Olhager E., and Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 171 (1997) 391-392
69. Anbu A.T., and Theodore A. Fluoxetine withdrawal syndrome in the newborn. Indian Pediatr. 4381 (2006) 66-69
70. Spencer M.J. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 92 (1993) 721-722
71. Mhanna M.J., Bennet II J.B., and Izatt S.D. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics. 100 (1997) 158-159
72. Hale T.W., Shum S., and Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr (Phila). 40 (2001) 681-684
73. Kwon P., and Lefkowitz W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann. 37 (2008) 131-133
74. Kent L.S., and Laidlaw J.D. Suspected congenital sertraline dependence. Br J Psychiatry. 167 (1995) 412-413
75. Santos R.P., and Pergolizzi J.J. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft). J Perinatol. 24 (2004) 392-394
76. Kwon P., and Lefkowitz W. Neonatal extrapyramidal movements. Neonatal withdrawal due to maternal citalo-pram and ondansetron use. Pediatr Ann. 37 (2008) 128-130
77. de Moor R.A., Mourad L., ter Haar J., and Egberts A.C. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy [in Dutch]. Ned Tijdschr Geneeskd. 147 (2003) 1370-1372
78. Sokolover N., Merlob P., and Klinger G. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. Can J Clin Pharmacol. 15 (2008) e188-e190
79. Eyal R., and Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry. 165 (2008) 651
80. Sanz E.J., De-las-Cuevas C., Kiuru A., et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet. 365 (2005) 482-487
81. Costei A.M., Kozer E., Ho T., et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 156 (2002) 1129-1132
82. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 60 (2003) 720-726
83. Cohen L.S., Heller V.L., Bailey J.W., et al. Birth outcomes following perinatal exposure to fluoxetine. Biol Psychiatry. 48 (2000) 996-1000
84. Goldstein D.J. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 15 (1995) 417-420
85. Oberlander T.F., Misri S., Fitzgerald C.E., et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 65 (2004) 230-237
86. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 158 (2004) 312-316
87. Zeskind P.S., and Stephens L.E. Maternal selective reuptake inhibitor use during pregnancy and newborn neuro-behavior. Pediatrics. 113 (2004) 368-375
88. Hendrick V., Stowe Z.N., Altshuler L.L., et al. Placental passage of antidepressant medications. Am J Psychiatry. 160 (2003) 993-996
89. Oberlander T.F., Warburton W., Misri S., et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 63 (2006) 898-906
90. Ferreira E., Carceller A.M., Agogué C., et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 119 (2007) 52-59
91. Pearson K.H., Nonacs R.M., Viguera A.C., et al. Birth outcomes following prenatal exposure to antide-pressants. J Clin Psychiatry. 68 (2007) 1284-1289
92. Suri R., Altshuler L., Hellemann G., et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 164 (2007) 1206-1213
93. Boucher N., Bairam A., and Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 28 (2008) 334-339
94. Jordan A.E., Jackson G.L., Deardorff D., et al. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. J Matern Fetal Neonatal Med. 21 (2008) 745-751
95. Oberlander T.F., Warburton W., Misri S., et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: Population-based study. Br J Psychiatry. 192 (2008) 338-343
96. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol. 12 Suppl B (1998) S5-S20
97. Kim J., Riggs K.W., Misri S., et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 61 (2006) 155-163
98. Wong-Riley M.T., and Liu Q. Neurochemical development of brain stem nuclei involved in the control of respiration. Respir Physiol Neurobiol. 149 (2005) 83-98
99. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry. 44 (1998) 151-162
100. Azmitia E.C. Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Neuropsychopharmacology 21 Suppl (1999) 33S-45S
101. Sullivan C.C., Du L., Chu D., et al. Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway. Proc Natl Acad Sci U S A 100 (2003) 12331-12336
102. Farrow K.N., Fliman P., and Steinhorn R.H. The diseases treated with ECMO: Focus on PPHN. Semin Perinatol. 29 (2005) 8-14
103. Walsh-Sukys M.C., Tyson J.E., Wright L.L., et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: Practice variation and outcomes. Pediatrics. 105 (2000) 14-20
104. Eddahibi S., Raffestin B., Hamon M., and Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension. J Lab Clin Med. 139 (2002) 194-201
105. Fornaro E., Li D., Pan J., and Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 176 (2007) 1035-1040
106. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 39 (2005) 492-503
107. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 354 (2006) 579-587
108. Källen B., and Olausson P.O. Maternal use of selective serotonin reuptake inhbitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 17 (2008) 801-806
109. Andrade S.E., McPhillips H., Loren D., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 18 (2009) 246-252
110. Nulman I., Rovet J., Stewart D.E., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. Am J Psychiatry. 159 (2002) 1889-1895
111. Oberlander T.F., Reebye P., Misri S., et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med. 161 (2007) 22-29
112. Mortensen J.T., Olsen J., Larsen H., et al. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and antiepileptics. Eur J Epidemiol. 18 (2003) 769-771
113. Turner M.S., May D.B., Arthur R.R., and Xiong G.L. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med. 261 (2007) 205-213
114. Kliegman R.M. Intracranial (intra-ventricular) hemorrhage. In: Behrman R.E., Kliegman R.M., and Arvin A.M. (Eds). Nelson Textbook of Pediatrics. 15th ed (1996), WB Saunders, Philadelphia, Pa 466-467
115. Mohan C.G., and Moore J.J. Fluoxetine toxicity in a preterm infant. J Perinatol. 20 (2000) 445-446
116. Salvia-Roigés M.D., Garcia L., Goncé-Mellgren A., et al. Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine [in Spanish]. Rev Neurol. 36 (2003) 724-726
117. Paroxetine. Can Adverse Drug Reaction Newslett 7 (1997) 953-954
118. Duijvestijn Y.C., Kalmeijer M.D., Passier A.L., et al. Neonatal intra-ventricular haemorrhage associated with maternal use of parox-etine. Br J Clin Pharmacol. 56 (2003) 581-582
119. Jhawar B.S., Ranger A., Steven D.A., and Del Maestro R.F. A follow-up study of infants with intracranial hemorrhage at full-term. Can J Neurol Sci. 32 (2005) 332-339
120. Maayan-Metzger A., Kuint J., Lu-betsky A., et al. Maternal selective serotonin reuptake inhibitor intake does not seem to affect neonatal platelet function tests. Acta Haematol. 115 (2006) 157-161
121. Salkeld E., Ferris L.E., and Juurlink D.N. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol. 28 (2008) 230-234
122. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur HeartJ. 3 Suppl K (2001) K70-K80
123. Witchel H.J., Pabbathi V.K., Hofmann G., et al. Inhibitory actions of the selective serotonin reuptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett. 512 (2002) 59-66
124. Dubnov G., Fogelman R., and Merlob P. Prolonged QT interval in an infant of a fluoxetine-treated mother. Arch Dis Child. 90 (2005) 972-973
125. Dubnov-Raz G., Juurlink D.N., Fogelman R., et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics. 122 (2008) e710-e715